Chronic Kidney Disease (CKD) refers to the gradual loss of kidney function over time. CKD drugs are used to treat various stages of CKD depending on the severity. Some of the common CKD drugs include angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARBs), potassium binders, calcium supplements, and phosphate binders. The increasing prevalence of diabetes and hypertension are some of the major risk factors leading to the growing demand for CKD drugs globally. These conditions, if left untreated, can damage kidneys over time and eventually lead to kidney failure.

The global Chronic Kidney Disease Drugs Market is estimated to be valued at US$ 13,220.0 Mn in 2023 and is expected to exhibit a CAGR of 4.5% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Get more insights on this topic: https://www.coherentmarketinsights.com/market-insight/chronic-kidney-disease-drugs-market-1713

Market key trends:

One of the key trends in the chronic kidney disease drugs market is the growing preference for combination therapies. Combination therapies help tackle multiple risk factors associated with CKD more effectively by targeting different pathways. For instance, combining ACE inhibitors or ARBs with potassium binders helps better control blood pressure and potassium levels in CKD patients. Similarly, combining phosphate binders with calcium or vitamin D supplements helps maintain mineral and bone metabolism. Manufacturers are focusing on developing fixed-dose combination drugs to improve patient adherence to treatment regimens. This is expected to drive the demand for combination CKD drugs over the forecast period.

Porter’s Analysis

Threat of new entrants: The threat is moderate as large capital investment is required for R&D of new drugs. Regulations also act as a barrier.

Bargaining power of buyers: The bargaining power of buyers is low as the treatment of chronic diseases highly depends on the patented drugs developed by key players.

Bargaining power of suppliers: The bargaining power of suppliers is moderate as key players have to depend on suppliers for raw materials and manufacturing facilities.

Threat of new substitutes: The threat is low as there are limited treatment options available for chronic kidney diseases.

Competitive rivalry: The competition is high among the key players to develop novel drugs for better treatment of chronic kidney diseases.

Key Takeaways

The global Chronic Kidney Disease Drugs Market is expected to witness high growth in the forecast period 2023 to 2030. The market size for 2024 is US$ 13,220.0 Mn.

Regional analysis: North America dominates the market and is expected to continue its dominance in the coming years owing to growing prevalence of chronic kidney diseases and availability of advanced healthcare facilities in the US and Canada. Asia Pacific is expected to be the fastest growing market due to increasing healthcare expenditures and raising awareness.

Key players: Key players operating in the Chronic Kidney Disease Drugs Market are Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharm. Sanofi dominates the market with its product portfolio to treat chronic kidney disease stage 3 to 5. Amgen holds significant share due to its drugs to treat anemia in CKD patients.